Experimental cell therapy offers hope for Tough-to-Treat blood disorder
NCT ID NCT07453836
Summary
This early-stage study is testing a new cell therapy called YTS109 for people with severe autoimmune hemolytic anemia who haven't responded to at least three previous treatments. Researchers will give patients modified immune cells and carefully monitor safety, side effects, and whether the treatment helps control the disease. The study will test different doses to find the safest and most effective amount.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.